<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684485</url>
  </required_header>
  <id_info>
    <org_study_id>SCD-044-19-16</org_study_id>
    <nct_id>NCT04684485</nct_id>
  </id_info>
  <brief_title>To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with&#xD;
      moderate to severe atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled study to determine the&#xD;
      effect of SCD-044 in subjects with moderate to severe atopic dermatitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI) score</measure>
    <time_frame>Week16</time_frame>
    <description>Percent change in Eczema Area and Severity Index (EASI). Based on gross morphological findings, scores will be assigned on a 4-point scale ['0' (absent), '1' (mild), '2' (moderate) and '3' (severe)] for each clinical sign..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validated Investigator's Global Assessment (vlGA) scale</measure>
    <time_frame>Week 32</time_frame>
    <description>Proportion of subjects who achieve a score of '0' or '1' on a 5-point vlGA scale. Based on morphological findings (overall appearance of the lesions at a given time point), scores will be assigned on a 5-point scale ('0' [clear] to 4 [severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eczema Area and Severity Index (EASI) score</measure>
    <time_frame>Week 32</time_frame>
    <description>Percent change in mean EASI score. Based on gross morphological findings, scores will be assigned on a 4-point scale ['0' (absent), '1' (mild), '2' (moderate) and '3' (severe)] for each clinical sign.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validated Investigator's Global Assessment (vlGA) scale.</measure>
    <time_frame>Week 32</time_frame>
    <description>Percent change in vIGA score. Based on morphological findings (overall appearance of the lesions at a given time point), scores will be assigned on a 5-point scale ('0' [clear] to 4 [severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Itch Numeric Rating Scale (WI-NRS)</measure>
    <time_frame>Week 32</time_frame>
    <description>Proportion of subjects who achieve ≥4-point improvement in WI-NRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORing Atopic Dermatitis (SCORAD) 50 and SCORAD 75 response</measure>
    <time_frame>Week 32</time_frame>
    <description>Proportion of subjects who achieve SCORAD 50 and SCORAD 75 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 32</time_frame>
    <description>Change from Baseline in quality of life measured by DLQI scores. Based on 10-item questionnaire on skin problems (0 to 3 scale). The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent body surface area (BSA)</measure>
    <time_frame>Week 32</time_frame>
    <description>Percent change from Baseline in BSA with atopic dermatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Oriented Eczema Measure (POEM) score</measure>
    <time_frame>Week 32</time_frame>
    <description>Change from Baseline in POEM score. Subjects will be asked to complete a 7-item questionnaire about their atopic dermatitis over the past week. Each of the seven questions is scored from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Week 32</time_frame>
    <description>Proportion of subjects with improvement in PGIC score. The subjects will be asked to assess if there has been an improvement or decline in clinical status using a 5-point scale depicting a subject's rating of overall improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Severity (PGIS)</measure>
    <time_frame>Week 32</time_frame>
    <description>Percent change in PGIS of disease score. The subjects will be asked to assess their overall impression of disease severity over the past week using a scale of None, Mild, Moderate or Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events.</measure>
    <time_frame>Week 36</time_frame>
    <description>Frequency, type and severity of adverse events from Baseline through Week 36</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Placebo of SCD-044 product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 Tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 Tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD-044 Tablets_Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SCD-044 Tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.</description>
    <arm_group_label>Placebo of SCD-044 product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 1</intervention_name>
    <description>SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.</description>
    <arm_group_label>SCD-044 Tablets_Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 2</intervention_name>
    <description>SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.</description>
    <arm_group_label>SCD-044 Tablets_Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCD-044_Dose 3</intervention_name>
    <description>SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.</description>
    <arm_group_label>SCD-044 Tablets_Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged at least 18 years.&#xD;
&#xD;
          2. Males and non-pregnant non-lactating females, diagnosed with chronic atopic dermatitis&#xD;
             for ≥ 1 year at Screening and Baseline based on Eichenfield revised criteria of&#xD;
             Hanifin and Rajka.&#xD;
&#xD;
          3. Moderate to severe atopic dermatitis at Screening and Baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female Subjects who are pregnant, nursing, or planning to become pregnant during study&#xD;
             participation or within 6 months of completing the study.&#xD;
&#xD;
          2. Known organ complications of Diabetes mellitus such as reduced renal function,&#xD;
             significant retinal pathology or neuropathy.&#xD;
&#xD;
          3. History or presence of uveitis&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head, Clinical development</last_name>
    <phone>912266455645</phone>
    <email>Clinical.Trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunpharma site no. 01</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

